8-K: Aflac Reports Solid Q2 2026 Earnings Amidst Market Fluctuations

Aflac Incorporated announced its second quarter 2026 financial results, reporting solid earnings per diluted share and strong capital positions, while navigating currency headwinds and market dynamics.

Summary

• Aflac Incorporated reported second quarter 2026 results with total revenues of $4.1 billion, a 1.0% decrease year-over-year.
• Net earnings were $825 million, or $1.63 per diluted share, a significant increase from $599 million, or $1.11 per diluted share, in the prior year.
• Adjusted earnings were $883 million, a decrease of 7.7% from $957 million in Q2 2025, with adjusted earnings per diluted share down 1.7% to $1.75.
• Excluding foreign currency impacts, adjusted earnings per diluted share increased 1.1% to $1.80.
• The company returned $1.3 billion to shareholders through $983 million in share repurchases and $309 million in dividends.
• Aflac Japan's pretax adjusted earnings in yen increased 3.4% to 118.2 billion, while in dollar terms, pretax adjusted earnings declined 6.2% to $741 million.
• Aflac U.S. pretax adjusted earnings were $370 million, a 4.6% decrease year-over-year, primarily due to higher benefits.
• Capital ratios remain strong, with an estimated regulatory ESR of 226% and a combined RBC ratio estimated above 600%.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a generally positive report, with solid earnings and strong capital ratios, though some areas like U.S. net earned premium growth and Japan's net earned premiums show slight declines or are at the lower end of guidance.

Positives

• Net earnings increased significantly by 37.7% to $825 million.
• Adjusted earnings per diluted share excluding foreign currency impact increased by 1.1% to $1.80.
• Annualized adjusted return on equity excluding foreign currency remeasurement was a strong 16.6%.
• Shareholder returns were robust, with $1.3 billion deployed through share repurchases ($983 million) and dividends ($309 million).
• Aflac Japan's pretax adjusted earnings in yen terms increased by 3.4%.
• Aflac Japan's pretax adjusted profit margin improved to 34.3% from 32.0% year-over-year.
• Aflac U.S. net earned premiums increased by 2.3% to $1.5 billion.
• Strong capital positions maintained with estimated regulatory ESR of 226% and combined RBC ratio above 600%.

Negatives

• Total revenues decreased by 1.0% to $4.1 billion.
• Adjusted earnings decreased by 7.7% to $883 million.
• Adjusted earnings per diluted share decreased by 1.7% to $1.75.
• Aflac Japan's net earned premiums in yen terms decreased by 3.7%, and in dollar terms by 12.7%.
• Aflac U.S. pretax adjusted earnings decreased by 4.6% to $370 million.
• Aflac U.S. pretax adjusted profit margin decreased to 20.9% from 22.5% year-over-year.
• Corporate and Other segment reported a pretax adjusted loss of $10 million, compared to a $20 million gain in the prior year.
• The weaker yen/dollar exchange rate had a negative $0.05 impact on adjusted earnings per share for the quarter.

Risks

• Difficult conditions in global capital markets and the economy, including inflation.
• Defaults and credit downgrades of investments.
• Global fluctuations in interest rates and exposure to significant interest rate risk.
• Concentration of business in Japan and limited availability of acceptable yen-denominated investments.
• Foreign currency fluctuations in the yen/dollar exchange rate.
• Significant valuation judgments in determination of expected credit losses recorded on the Company's investments.
• Extensive regulation and changes in law or regulation by governmental authorities.
• Catastrophic events, including but not limited to, epidemics, pandemics, natural disasters, war, or terrorism.

Future Outlook

The company expects its net earned premium growth rate for 2026 to be just below the previously guided range of 3% to 6%. For Aflac Japan, the full-year 2026 benefit ratio is now expected to be at the high end of the guidance range of 60% to 63%, excluding the annual actuarial assumption review in Q3.

Management Comments

• "Aflac delivered solid earnings for the quarter and for the first six months. These results reflect execution of our strategy, driving long-term value for shareholders."
• "In Japan, we have secured new opportunities through successful product initiatives including Anshin Palette (medical insurance), Miraito (cancer insurance) and Tsumitasu (life insurance)."
• "In the U.S., our focus is on meeting the evolving needs of employers and their employees with supplemental health products and related benefits."
• "We continue to pursue more profitable growth and the tactical, opportunistic deployment of capital."
• "We treasure our 2025 milestone of 43 consecutive years of dividend increases, and the Board set us on a path to extend this record in 2026."
• "We intend to continue our balanced approach of investing in growth and driving long-term value."
• "Overall, we view these results in the quarter as solid."
• "We will continue to be flexible and tactical in the way we manage the balance sheet and deploy capital in order to drive strong risk-adjusted ROE with a meaningful spread to our cost of capital."

Industry Context

StockSavvy.ai notes that Aflac's results are being reported in a complex environment characterized by ongoing inflationary pressures in Japan, fluctuating currency exchange rates, and evolving market needs for supplemental health products in the U.S. The company's strategic product initiatives in Japan and focus on employer/employee needs in the U.S. align with broader industry trends of adapting to economic conditions and customer demands.

Comparison to Industry Standards

• Aflac's adjusted ROE excluding foreign currency remeasurement of 16.6% is a solid performance, though direct comparison to specific industry benchmarks is difficult without knowing the exact composition of competitors' non-GAAP measures.
• The company's focus on product innovation in Japan (Anshin Palette, Miraito, Tsumitasu) aims to maintain market leadership against competitors in the cancer and medical insurance sectors.
• In the U.S., Aflac's position as the No. 1 provider of supplemental health insurance products is a key differentiator against other health and life insurers operating in the supplemental benefits space.

Stakeholder Impact

• Shareholders: Continued return of capital through dividends and share repurchases, aiming for strong risk-adjusted ROE.
• Policyholders: Continued focus on providing financial protection and meeting evolving needs with supplemental health products.
• Employees/Associates: Company aims to attract and retain qualified personnel.
• Regulators: Company operates within an extensive regulatory environment and must comply with changes in law and regulation.

Next Steps

• Continue to pursue profitable growth and tactical capital deployment.
• Invest in growth initiatives.
• Drive long-term value for shareholders.
• Continue to monitor and manage capital positions.
• Repurchase stock and pay dividends.
• Continue to adapt product offerings to meet evolving customer needs.

Key Dates

Recommendation

The results show a mixed performance with strong net earnings but a decline in adjusted earnings, influenced by currency fluctuations and investment impacts. While capital positions are robust and shareholder returns are consistent, the slight decrease in adjusted EPS and revenue, coupled with ongoing risks like currency volatility and economic conditions, suggest a 'hold' recommendation pending clearer signs of sustained adjusted earnings growth and a more favorable macroeconomic outlook.

Keywords

Aflac Incorporated, Q2 2026 Earnings, Supplemental Insurance, Japan Insurance, U.S. Insurance, Financial Results, Adjusted Earnings, Shareholder Returns